Bioconjugate Chemistry

Design, Synthesis, and X-ray Analysis of a Glycoconjugate Bound to *Mycobacterium tuberculosis* Antigen 85C

Diaa A. Ibrahim,[†] Julie Boucau,[‡] Daniel H. Lajiness,[‡] Sri Kumar Veleti,[‡] Kevin R. Trabbic,[‡] Samuel S. Adams,[‡] Donald R. Ronning,^{*,‡} and Steven J. Sucheck^{*,‡}

[†]National Organization for Drug Control & Research, Cairo, Gizaa, Egypt

[‡]Department of Chemistry, The University of Toledo, 2801 W. Bancroft Street, Toledo, Ohio 43606, United States

(5) Supporting Information

ABSTRACT: Tuberculosis (TB) is a global health threat with nearly 500 000 new cases of multidrug-resistant TB estimated to occur every year, so new drugs are desperately needed. A number of current antimycobacterial drugs work by interfering with the biosynthesis of key components of the mycolylarabinogalactan (mAG). In light of this observation, other enzymes involved in the synthesis of the mAG should also serve as targets for antimycobacterial drug development. One potential target is the Antigen 85 (Ag85) complex, a family of mycolyltransferases that are responsible for the transfer of mycolic acids from trehalose monomycolate (TMM) to the



arabinogalactan. Virtual thiophenyl–arabinoside conjugates were docked to antigen Ag85C (PDB code: 1va5) using Glide. Compounds with good docking scores were synthesized by a Gewald synthesis followed by linking to 5-thioarabinofuranosides. The resulting thiophenyl-thioarabinofuranosides were assayed for inhibition of mycoyltransferase activity using a 4methylumbelliferyl butyrate fluorescence assay. The conjugates showed K_i values ranging from 18.2 to 71.0 μ M. The most potent inhibitor was soaked into crystals of *Mycobacterium tuberculosis* antigen 85C and the structure of the complex determined. The X-ray structure shows the compound bound within the active site of the enzyme with the thiophene moiety positioned in the putative α -chain binding site of TMM and the arabinofuranoside moiety within the known carbohydrate-binding site as exhibited for the Ag85B-trehalose crystal structure. Unexpectedly, no specific hydrogen bonding interactions are being formed between the arabinofuranoside and the carbohydrate-binding site of the active site suggesting that the binding of the arabinoside within this structure is driven by shape complementarily between the arabinosyl moiety and the carbohydrate binding site.

INTRODUCTION

Tuberculosis (TB) is a global health threat with nearly 500 000 new cases of multidrug-resistant TB (MDF-TB) estimated to occur every year. More concerning is that, since 2006, strains of extensively drug-resistant TB (XDR-TB), estimated to be 4% of MDR-TB, have been reported in over 50 countries. It is also estimated that 30–40% of XDR-TB is untreatable with the current antitubercular drug repertoire.¹ On this basis, it is clear that new approaches to treating the disease are needed. Several of the current drugs used to treat TB work by interfering with mycobacterial cell wall synthesis.² Contained within the structure of the cell is a unique macromolecular structure called the mycolylarabinogalactan (mAG), which is composed of the arabinogalactan (AG) and mycolic acids.³ The structure serves as a protective barrier for the organism and limits the diffusion of hydrophobic and hydrophilic drugs.⁴

A number of antimycobacterial drugs, e.g., ethambutol,^{5,6} isoniazid,⁷ and ethionamide,⁸ work by interfering with the biosynthesis of key components of the mAG. In light of this observation, other enzymes involved in the synthesis of the mAG may also serve as targets for antimycobacterial drug development. One potential target that has attracted some

attention is the Antigen 85 complex (Ag85). Ag85 represents a family (Ag85A, Ag85B, and Ag85C) of homologous mycolyltransferases that are responsible for the synthesis of trehalose-6.6'-dimycolate (TDM) from trehalose-6-monomycolate $(TMM)^{9-12}$ and for transfer of mycolic acids from TMM to the arabinogalactan (AG).^{13,14} Results from inhibitor studies suggest that Ag85 is essential for bacterial viability. For example, 6-azido-6-deoxytrehalose, a known inhibitor of Ag85s, has been shown to completely inhibit the growth of Mycobacterium aurum a surrogate for Mycobacterium tuberculosis.¹⁵ Other studies which support the essentiality of Ag85 include the use of Ag85-specific antisense oligonucleotides, which were shown to reduce Mycobacterium tuberculosis growth as well significantly enhance bacterial sensitivity to isoniazid.^{16,17} Similarly, an Ag85A knockout strain of Mycobacterium smegmatis exhibits increased sensitivity to drugs that target peptidoglycan biosynthesis, i.e., vancomycin and imipenem.¹

Received:August 7, 2012Revised:November 7, 2012Published:November 29, 2012

ACS Publications © 2012 American Chemical Society



Figure 1. Proposed mechanism for Ag85-mediated mycolyl transfer resulting in the formation of mAG and TDM.

A variety of putative Ag85 inhibitors have been described. For example, alkyl phosphonates¹⁹ expected to mimic the tetrahedral intermediate of Ag85s were shown to be active against Mycobacterium avium and inhibited mycolyltransferase activity.²⁰ Other examples include trehalose-based substrate analogues that contain aliphatic chains which showed activity against *Mycobacterium smegmatis*,²¹ and related compounds consisting of 6,6'-bis(sulfonamido) and N,N'-dialkylamino derivatives active against *Mycobacterium tuberculosis* and *Mycobacterium avium*.²² Further, a fluorophosphonate derivative of trehalose was shown to form a covalent adduct with the active site serine of M. tuberculosis Ag85C.²³ More recently, we have found arabinofuranoside-based substrate analogues containing S-alkyl chains (Figure 2) that inhibited the growth of *Mycobacterium smegmatis*;²⁴⁻²⁶ however, the latter compounds did not inhibit acyltransferase activity using our recently developed colorimetric acyltransferase assay.²⁷ On the other hand, α -ketoester derivatives of arabinofuranosides showed weak (mM) inhibitory activity against Ag85C but were inactive in cell-based assays.²⁸ In light of this data, we thought it was necessary to identify more potent Ag85 inhibitors.

The crystal structures of secreted forms of Ag85A,²⁹ Ag85B,^{30,31} and Ag85C^{29,32,33} from *Mycobacterium tuberculosis* have all been determined. The structures reveal an α/β -hydrolase fold, with a catalytic triad formed by Ser124, Glu228, and His260 (Ag85C numbering). The carbohydrate binding site is highly conserved between the three acyltransferases. Near the catalytic triad is a binding site for the carbohydrate moiety with a negative electrostatic potential, as well as a hydrophobic tunnel, well-suited to accommodate the shorter α -branch of the mycolyl moiety. Additionally, a nearby shallow cleft possessing hydrophobic character may bind the longer β -branch of the

mycolyl moiety. However, it seems more likely that the β branch of the mycolyl moiety will remain embedded in the mycobacterial outer membrane during the mycolyltransfer reaction. According to the proposed mechanism of the catalytic mycolyl transfer reaction, Ser124 attacks the carboxyl carbon of TMM to give a mycolyl-enzyme intermediate and free trehalose. In the next step, the 6-OH group of a second TMM molecule attacks the carboxylate carbon of the acylenzyme intermediate to produce TDM. Both the acylation and deacylation steps proceed via a high-energy tetrahedral transition state.³³ In the case of the formation of the mAG, the terminal and penultimate primary hydroxyl groups of arabinan serve as acyl acceptors (Figure 1). Recombinant Ag85C has been shown to catalyze this reaction in vitro.³⁴ On the basis of this model and the available crystallographic data, we envisioned conjugates that would contain both a rigid, druglike moiety, that could mimic the affinity of the mycolyl moiety and could also be conjugated to a fragment of the arabinan for selectivity (Figure 2). We reasoned that the carbohydrate component of compounds could occupy the carbohydrate binding site on Ag85s and provide specificity, while a hydrophobic component could occupy the pocket leading into the tunnel proposed to accommodate the α -branch of the mycolyl moiety. The main difficulty in this endeavor would be to select an appropriate motif that could accommodate at least a portion of the putative mycolyl moiety binding site. Our interests were drawn toward 2-amino-4,5,6,7-tetrahydrobenzo-[b] thiopenes due to their structural similarity with ebselen (Figure 2). We have identified the latter compound as a nanomolar inhibitor of Ag85s via the screening of the NIH Clinical Collection.³⁵ The ability of this motif to accommodate the putative binding pocket of mycolyl moiety was confirmed

Bioconjugate Chemistry



Figure 2. Design of arabinose-thiophene conjugates designed to act as inhibitors of Ag85s. Structures of an S-alkyl arabinofuranoside, ebselen, and I3-AG85.

by a docking strategy. Once identified, we noted that the 2amino-4,5,6,7-tetrahydrobenzo[b]thiophene had been used extensively as a scaffold for enzyme inhibitor development.³⁶⁻⁴⁰

We have previously disclosed the structure of 1a (Scheme 1).^{41,42} We also note, 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (1b, Scheme 1) has been independently identified as a binder of Ag85C using an ¹⁵N-HSQC NMR spectroscopy-based fragment screening protocol.43,44 The resulting thiophene was found to selectively inhibit the

Scheme 1. Synthesis of Tetrahydrobenzo [b] thiophenes^a

growth of *M. smegmatis* with an MIC of 50–100 μ g/mL.³⁹ More recently, 2-amino-6-propyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonitrile (I3-AG85, Figure 2) was identified as a second-generation inhibiter with MICs of 100 μ g/mL against M. tuberculosis. The I3-AG85 reduced survival of M. tuberculosis inside macrophages and at a 100 μ M concentration. The compound inhibited the growth of 7 MDR and 3 XDR M. tuberculosis strains at 200 µM or lower. Finally, I3-AG85 was shown to inhibit the synthesis of TDM. The generalized structures, which we explored in docking studies, are shown in Figure 2.

EXPERIMENTAL PROCEDURES

Biological Methods. K_M Determination for 4-MUB. Ag85C was purified as described previously.²⁷ All assays were performed under atmospheric pressure at 37 °C in a 384-well format on a Synergy H4 Hybrid Multi-Mode Microplate Reader (Biotek). All 4-methylumbelliferyl butyrate (4-MUB) stock solutions were made and stored in 100% DMSO at -20°C. Excitation and emission wavelengths, 365 and 450 nm, respectively, were used to monitor the production of the 4methylumbelliferone (4-MU) at 20 s intervals for 30 min. For each reaction, a master mix was made consisting of 600 nM Ag85C, 10 mM trehalose, and an appropriate volume of 20 mM bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Acros Organics) for an overall reaction volume of 50 μ L. 0.5 μ L of 4-MUB was added from each corresponding stock solution to reach the desired substrate concentration (25–400 μ M). The data were normalized using negative controls where no Ag85C



^aReagent and conditions: (i) sulfur, N-ethylmorpholine, EtOH, 1a (27%), 1b (33%); (ii) Et₃N, CH₂Cl₂, rt, 2a (11%), 2b (9%), 2c (15%), 2d (29%); (iii) KSCOCH₃, DMF, rt, **3a** (62%), **3b** (66%), **3c** (96%), **3d** (78%); (iv) toluene, 112 °C, 3 h (53%); (v) CH₂Cl₂, rt, **4a** (39%), **4b** (67%).

was added. The background fluorescence from the negative control was subtracted from the intensities measured from the enzyme-catalyzed reaction. To correlate relative fluorescence intensity with the amount of product, the fluorescence of 4-MU (1-1000 nM) was determined using reaction conditions. RFU/ min rates from the enzyme-catalyzed reaction were directly correlated to the amount of 4-MU produced per minute using the equation for the line of best fit, using *Microsoft Excel. GraphPad Prism 5* software was used to determine Michelis-Menten parameters via nonlinear regression analysis.

Inhibition Assays. All stock solutions for each compound were made and stored in 100% DMSO. Excitation and emission scans of each compound to be tested were conducted to avoid regions of overlap with 4-methylumbelliferone. The excitation and emission wavelengths used for each compound were as follows: SA-1, $\lambda_{ex} = 320$ nm, $\lambda_{em} = 500$ nm; KT-1-189, $\lambda_{ex} = 380$ nm, $\lambda_{\rm em}$ = 500 nm; DI-1, $\lambda_{\rm ex}$ = 380 nm, $\lambda_{\rm em}$ = 500 nm; DI-2, $\lambda_{\rm ex}$ = 320 nm, $\lambda_{\rm em}$ = 450 nm. All fluorescence intensities were determined at 20 s intervals over 30 min. The identities and concentrations of the reaction components used for determining the $K_{\rm M}$ were employed in these reactions as well; however, the 4-MUB concentration was held constant at 100 μ M. 0.5 μ L of each tested inhibitor was added from its corresponding stock solution to give final concentrations ranging from 20 μ M to 320 μ M. Inhibition was determined by comparing the relative rate of the reaction performed with inhibitor against a reaction that contained no inhibitor (v_i'/v_i) where v_i' and v_i are steady-state rates with and without inhibitor, respectively). The equilibrium dissociation constant (K_i) for each inhibitor was obtained by fitting the data into the equation below using Prism:

$$\frac{v_i'}{v_i} = \frac{K_{\mathrm{M}} + [\mathrm{S}]}{K_{\mathrm{M}} + [\mathrm{S}] + \frac{K_{\mathrm{M}}[\mathrm{I}]}{K}}$$

 $K_{\rm M}$ is the Michelis-Menten constant for 4-MUB; [S] and [I] are the concentrations of 4-MUB and inhibitor, respectively.

Protein Crystallization, Diffraction, and Model Building. The Ag85C crystals were obtained using the hanging drop method where 1 μ L of purified Ag85C was combined with 1 μ L of the well solution containing 0.3 M ammonium sulfate and 0.1 M sodium acetate. These crystals were prepared for X-ray diffraction studies by adding 1 μ L of a 10.7 mM solution of 13a dissolved in an 80% v/v solution of DMSO to the 2 μ L crystallization drop. These crystals were incubated at 16 °C for 2 days prior to data collection. Crystals were cryoprotected by adding glycerol directly to the drop containing the Ag85C crystal and 13a. Diffraction data were collected at the LS-CAT beamline at the Advanced Photon Source using a wavelength of 0.978 56 Å. Data were reduced using HKL2000.45 Molecular replacement was performed using EPMR.46 Manual model building was performed using Coot.47 Refinement, building inhibitor 13a, and addition of glycerol and water molecules was performed using Phenix.^{48,49} Glycerol molecules were manually fit to $F_{0} - F_{c}$ density using Coot.

Kirby-Bauer Disk Diffusion Assay. Disk diffusion assays were adapted from methods outlined by the NCCLS and Wang et al.^{21,50} Mycobacterium smegmatis ATCC 14468 was inoculated into Middlebrook 7H9 containing 0.2% glycerol and ADC enrichment, respectively. The inocula were incubated for approximately 48 h at 37.5 °C at 160 rpm. The bacteria were plated on agar (Lennox or Middlebrook 7H10 containing 0.5% glycerol and OADC Enrichment) using sterile cotton-tipped applicators. Aliquots (10 μ L) of arabinose derivatives dissolved

in DMSO (20 mg/mL) and INH (500 μ g/mL) were applied to 6-mm-diameter sterile paper disks. The plates were incubated at 37 °C for 24 h and then analyzed.

Synthetic Methods. *Ethyl 2-Amino-4,5,6,7tetrahydrobenzo[b]thiophene-3-carboxylate (1a).* Cyclohexanone (30.0 mL, 290 mmol), sulfur (9.30 g, 290 mmol), *N*ethylmorpholine (25.2 mL, 200 mmol), ethyl cyanoacetate (51.5 mL, 290 mmol) and ethanol (320 mL) were combined in a round-bottom flask and stirred at room temperature. After 3 h of continuous stirring, the reaction was complete and filtered to remove sulfur. The solvent was evaporated under reduced pressure. The product was extracted with 200 mL of methanol and crystallized by adding 100 mL of water to the methanol solution. The crystals were filtered and rinsed with cold 1:1 methanol–water: yield = 17.6 g (27%); mp = 117–119 °C (Lit:⁵¹113–117 °C); R_f = 0.55 (4:1 hexanes–ethyl acetate); mass spectrum (ESIMS), m/z = 226 (M+H)⁺, C₁₁H₁₀₆NO₂S requires 226.

2-Amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carbonitrile (1b). Cyclohexanone (30.0 mL, 290 mmol), malonitrile (19.8 g, 290 mmol), sulfur (9.30 g, 290 mmol), and 25.2 mL of *N*-ethylmorpholine (25.2 mL, 200 mmol) were combined in a round-bottom flask and stirred at room temperature. After 3 h of continuous stirring, the reaction was complete and filtered to remove sulfur. The solvent was evaporated under reduced pressure, and the product was extracted by 200 mL of methanol. The product was crystallized by adding 100 mL of water to the methanol solution. The crystals were filtered and rinsed with a solution of cold 4:1 methanol–water: yield = 17.0 g (33%); mp = 147–149 °C (Lit:⁵² 147 °C); $R_f = 0.35$ (9:1 hexane—ethyl acetate); mass spectrum (ESIMS), m/z = 179(M+H)⁺, C₉H₁₁N₂S requires 179.

Ethyl 2-[(2-Chloroacetyl)amino]-4,5,6,7-tetrahydrobenzo-[b]thiophene-3-carboxylate (2a).⁵³ Compound (1a) (0.500 mg, 2.2 mmol) was treated with chloroacetyl chloride (0.35 mL, 4.4 mmol) in chloroform (5 mL) and reaction was refluxed for 3 h. The reaction was analyzed for completion by TLC with 9:1 hexanes-ethyl acetate. The reaction solution was concentrated under reduced pressure and the residue crystal-lized from chloroform-hexanes: yield 0.231 g (34%); mp = 118–121 °C (Lit:⁵⁴ 115–117 °C); $R_f = 0.49$ (9:1 hexanes-ethyl acetate); ¹H NMR (CDCl₃, 400 MHz): δ 1.39 (t, J = 7.2 Hz, 3H), 1.79–1.81 (m, 4H), 2.66 (t, J = 4.4 Hz, 2H), 2.79 (t, J = 5.2 Hz, 2H), 4.26 (s, 2H), 4.36 (q, J = 7.2 Hz, 2H), 12.14 (br. s, 1H, NH); mass spectrum (ESIMS), m/z = 324 (M+Na)⁺, $C_{13}H_{16}$ ClNO₃S requires 324.

Ethyl 2-[(4-Chlorobutanoyl)amino]-4,5,6,7tetrahydrobenzo[b]thiophene-3-carboxylate (2b). Compound 1a (1.13 g, 5.00 mmol), triethyl amine (2.10 mL, 15.0 mmol), and dry dichloromethane (20.0 mL) were combined in a round-bottom flask. 4-Chlorobutyryl chloride (1.20 mL, 15.0 mmol) was added and the reaction stirred at room temperature for 6 h. The solution was washed with 30.0 mL of 1 M HCl followed by 30.0 mL of saturated sodium bicarbonate solution. The organic layer was dried using anhydrous sodium sulfate, filtered, and rinsed with dichloromethane. The filtrate was evaporated to dryness, and the product was purified by flash column chromatography on silica gel $(30 \text{ mm} \times 150 \text{ mm})$. The column was eluted with 3:1 chloroform-hexanes and concentrated to dryness under reduced pressure. The residue was crystallized from ethyl acetate-hexanes. After cooling to room temperature, the crystals were filtered and rinsed with 20.0 mL of cold 10:1 hexanes-ethyl acetate: yield = 0.47 g (9.4%); mp = 70–72 °C; $R_f = 0.63$ (3:1 chloroform–hexanes); ¹H NMR (DMSO- d_{60} 600 MHz): δ 1.39 (t, J = 6.8 Hz, 3H), 1.54–1.57 (m, 2H), 1.79–1.80 (m, 4H), 2.23 (p, J = 7.2 Hz, 2H), 2.65–2.69 (m, 2H), 2.78 (t, J = 6 Hz, 2H), 3.65 (t, J = 6Hz, 2H), 4.33 (q, J = 7.2 Hz, 2H), 11.35 (s, 1H); ¹³C NMR (DMSO- d_{61} 150 MHz) δ : 14.5, 23.0, 23.1, 24.5, 26.5, 27.9, 33.6, 44.3, 60.7, 111.7, 126.9, 130.9, 147.6, 166.8, 168.8; mass spectrum (HRMS), m/z = 330.0910 (M+H)⁺, C₁₅H₂₁ClNO₃S requires 330.0931.

2-Chloro-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2yl)acetamide (2c). Compound (1b) (0.500 g, 2.8 mmol) was treated with chloroacetyl chloride (0.44 mL, 5.61 mmol) in chloroform (5 mL). The reaction was refluxed for 3 h. The reaction was analyzed for completion by TLC with 9:1 hexanes-ethyl acetate. The reaction solution was concentrated under reduced pressure. The residue is crystallized from chloroform-hexanes: yield 0.418 g (59%); mp = 180–183 °C (Lit:²⁴ 171–173 °C); R_f = 0.3 (9:1 hexanes-ethyl acetate); ¹H NMR (CDCl₃, 400 MHz); δ 1.85 (m, 4H), 2.62 (t, *J* = 5.6 Hz, 2H), 2.66 (t, *J* = 4.4 Hz, 2H), 4.28 (s, 2H), 9.38 (s, 1H); mass spectrum (ESIMS), m/z = 277 (M+Na)⁺, C₁₁H₁₁CIN₂OS requires 277.

4-Chloro-N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2yl)butanamide (2d). Compound 1b (1.07 g, 6.00 mmol), triethyl amine (2.50 mL, 18.0 mmol), and dry dichloromethane (20 mL) were combined in a round-bottom flask. The reaction occurred under dry nitrogen and 4-chlorobutyryl chloride (2.03 mL, 18.0 mmol) was added. The reaction was analyzed for completion by TLC using 3:1 hexanes-ethyl acetate. The solution was washed with 30 mL of 1 M HCl in a separatory funnel; the organic layer was then washed with 30 mL saturated sodium bicarbonate solution. The organic layer was dried using anhydrous sodium sulfate, filtered, and rinsed with dichloromethane. The product was concentrated to dryness under reduced pressure. The product was decolorized using carbon decolorizing charcoal in ethyl acetate solution. The solution was filtered, concentrated, and crystallized by chloroform and hexanes. Crystals were rinsed and filtered with cold 1:1 chloroform-hexanes: yield = 1.48 g (29%); mp = 158-161 °C (Lit:⁵⁴ mp = 186–187 °C, Lit:⁵⁵ mp = 143–146 °C); $R_f = 0.5$ (3:1 hexanes-ethyl acetate); ¹H NMR (CDCl₃, 400 MHz): δ 1.92-1.87 (m, 2H), 2.15 (p, J = 6.4 Hz, 2H), 2.70 (t, J = 5.6Hz, 1H), 2.77 (t, J = 4.4 Hz, 1H), 2.89 (t, J = 7.2 Hz, 2H), 3.63 $(t, J = 6.0 \text{ Hz}, 2\text{H}) 9.08 (s, 1\text{H}); {}^{13}\text{C} \text{ NMR} (\text{CDCl}_3, 100 \text{ MHz}):$ δ 22.3, 23.3, 24.1(2), 32.8, 27.9, 44.4, 92.5, 115.0, 128.2, 130.9, 147.7, 169.6; mass spectrum (ESIMS), $m/z = 283 (M+H)^+$, C₁₃H₁₆ClN₂OS requires 283.

2-(Acetylthio)alkanamido-4,5,6,7-tetrahydrobenzo[b]thiophene derivatives 3a-d. Potassium thioacetate (0.423 mg, 3.78 mmol) was added to a solution of 2-(chloroalkyl) aminothiophene derivatives 2a-d (3.15 mmol) in anhydrous DMF (25 mL) under nitrogen. The reaction mixture was stirred overnight, and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (15 mL), and the resulting solution was washed with water. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and the solvent was removed under reduced pressure. The residue was purified by flash chromatography to give the acetylthio derivatives 3a-d.

Ethyl 2-(2-(Acetylthio)acetamido)-4,5,6,7tetrahydrobenzo[b]thiophene-3-carboxylate (3a). Potassium thioacetate (43.9 mg, 0.385 mmol) was added to a conical vial containing a solution of 2-(chloroalkyl) aminothiophene derivative 2a (100 mg, 0.332 mmol) in anhydrous DMF (5.0 mL) under nitrogen. The reaction mixture was stirred at room temperature for 20 h and diluted with ethyl acetate (10.0 mL). The resulting solution was washed with water and the combined organic extracts were dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (30 mm × 150 mm) eluting with 1:4 ethyl acetatehexanes. The solid could be crystallized from ethyl acetatehexanes to generate yellow microcrystals: yield = 68.9 mg (62%); mp = 115–116 °C; $R_f = 0.48$ (1:4 ethyl acetate– hexanes); ¹H NMR (CDCl₃, 400 MHz): δ 1.38 (t, J = 7.2 Hz, 3H) 1.77-1.78 (m, 4H), 2.46 (s, 3H), 2.63-2.64 (m, 2H), 2.76-2.77 (m, 2H), 3.82 (s, 2H), 4.36 (q, J = 6.8 Hz, 2H), 11.68 (s, 1H); ¹³C NMR (CDCl₃, 150 MHz): δ 14.3, 22.8, 22.9, 24.3, 26.3, 30.2, 33.0, 60.5, 112.3, 127.1, 131.0, 146.6, 164.8, 166.2, 194.0; mass spectrum (HRMS), m/z = 364.0630 $(M+Na)^+$, $C_{15}H_{19}NNaO_4S_2$ requires 364.0653.

Ethyl 2-(4-(Acetylthio)butanamido)-4,5,6,7tetrahydrobenzo[b]thiophene-3-carboxylate (**3b**). The solid could be crystallized from ethyl acetate—hexanes to generate yellow needles: yield 0.78g (66%); mp = 74.0–74.5 °C; ¹H NMR (CDCl₃, 600 MHz): δ 1.38 (t, J = 7.2 Hz, 3H), 1.78 (m, 4H), 2.03 (m, 2H), 2.33 (s, 3H), 2.54 (m, 2H), 2.63 (m, 2H), 2.76 (m, 2H), 2.97 (m, 2H), 4.37 (q, J = 6.8 Hz, 2H), 11.28 (s, 1H); ¹³C NMR (CDCl₃, 600 MHz): δ 14.3, 22.8, 22.9, 24.3, 25.0, 26.3, 28.3, 30.6, 35.2, 60.5, 111.4, 126.6, 130.6, 147.3, 166.6, 195.5; mass spectrum (HRMS), m/z = 392.0938 (M +Na)⁺, C₁₇H₂₃NNaO₄S₂ requires 392.0966.

4-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-ylamino)-4-oxoethyl ethanethioate (**3c**). The solid could be crystallized from ethyl acetate—hexanes to generate yellow needles: yield 0.89g (96%); mp = 170.0–170.5 °C; ¹H NMR (CDCl₃, 600 MHz): δ 1.83–1.79 (m, 4H), 2.47 (s, 3H), 2.58– 2.57 (m, 2H), 2.63–2.59 (m, 2H), 3.78 (s, 2H), 9.48 (s, 1H); ¹³C NMR (CDCl₃, 600 MHz): δ 22.0, 23.0, 23.9, 23.9, 30.2, 32.8, 94.1, 113.9, 128.6, 131.1, 146.1, 165.1, 196.5; mass spectrum (ESIMS), m/z = 295 (M+H)⁺, C₁₃H₁₅N₂O₂S₂ requires 295.

¹4-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-ylamino)-4-oxobutyl ethanethioate (**3d**). Yield 0.79g (78%); ¹H NMR (CDCl₃, 600 MHz): δ 1.85 (m, 4H), 2.03 (m, 2H), 2.33 (m, 2H), 2.34 (s, 3H), 2.55 (m, 4H), 2.95 (m, 2H), 9.40 (s, 1H); ¹³C NMR (CDCl₃, 600 MHz): δ 22.8, 22.9, 24.3, 25.0, 26.3, 29.3, 32.6, 34.2, 91.5, 114.4, 128.6, 132.6, 148.3, 170.8, 196.5; mass spectrum (HRMS), m/z = 322.0527 (M+Na)⁺, requires 322.0548.

Ethyl 2-[(4-Bromobutanoyl)amino]-4,5,6,7tetrahydrobenzo[b]thiophene-3-carboxylate (4a). Compound 1a (0.600 g, 2.66 mmol) was dissolved in dichloromethane (15 mL) and cooled to 0 °C. 4-Bromobutyryl chloride (0.366 mL, 3.16 mmol) was added dropwise under nitrogen atmosphere. The reaction was stirred continuously for 1.5 h and analyzed for completion by TLC using 3:1 (hexanes-ethyl acetate). Upon completion, the reaction mixture was washed with brine $(3 \times 20 \text{ mL})$, satd NaHCO₃ $(3 \times 20 \text{ mL})$, and 1 N HCl $(3 \times 20 \text{ mL})$. The organic layer was dried using anhydrous sodium sulfate, filtered, and rinsed with dichloromethane. The crude product was purified by flash column chromatography on silica gel (30 mm × 150 mm) using 1:3 hexanes-ethyl acetate as the eluent. The product was concentrated to dryness and recrystallized from hot hexanes: yield = 0.392 g (39%); mp = 80-81 °C; $R_f = 0.5$ (3:1 hexanes-ethyl acetate); ¹H NMR (CDCl₃, 400 MHz): δ 1.39 (t, J = 6.8 Hz, 2H, 3H), 1.77–1.79 (m, 4H), 2.31 (p, J = 6.4 Hz, 2H), 2.62–2.67 (m, 4H), 2.69–2.77 (m, 2H), 3.52 (t, J = 6.4 Hz, 2H), 4.33 (p, J = 7.2 Hz, 2 H), 11.34 (s,1H); ¹³C NMR (CDCl₃, 400 MHz) δ 14.5, 23.0, 23.1, 24.5, 26.5, 28.0, 33.0, 34.9, 60.7, 111.6, 126.9, 131.0, 147.4, 166.3, 168.7; mass spectrum (HRMS), m/z = 396.0253 (M+H)⁺ C₁₅H₂₀BrNO₃SNa requires 396.0245; Anal. Calcd for C₁₅H₂₀BrNO₃S: C, 48.13; H, 5.39; N, 3.74. Found: C, 48.78; H, 5.41; N, 3.77.

4-Bromo-N-(3-cvano-4,5,6,7-tetrahvdrobenzo[b]thiophen-2-yl)butanamide (4b). Compound 1b (1.00 g, 5.61 mmol) was dissolved in dichloromethane (25 mL) and cooled to 0 °C. 4-Bromobutyryl chloride (0.773 mL, 6.68 mmol) was added dropwise under nitrogen atmosphere and the reaction was stirred continuously for 1.5 h. The reaction was analyzed for completion by TLC using 3:1 hexanes-ethyl acetate. Upon completion, the reaction mixture was washed with brine $(3 \times$ 20 mL), satd NaHCO₃ (3 \times 20 mL), and 1 N HCl (3 \times 20 mL). The organic layer was dried using anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel $(30 \text{ mm} \times 150 \text{ mm})$ using 1:3 hexanes-ethyl acetate as the eluent. The product was concentrated to dryness and recrystallized using dichloromethane-hexanes: yield = 1.23 g (67%); mp = 173-174 °C; $R_f = 0.5$ (3:1 hexanes-ethyl acetate); ¹H NMR (CDCl₃, 600 MHz): δ 1.53–1.59 (m, 1H), 1.83-1.84 (m, 4H), 2.31 (p, J = 6.6 Hz, 2H), 2.60-2.64 (m, 4H), 2.69 (t, J = 7.2 Hz, 2H), 3.53 (t, J = 6.0 Hz, 2H), 8.57 (m,1H, NH); ¹³C NMR (CDCl₃, 600 MHz): δ 22.3, 23.3, 24.1, 24.2, 27.9, 33.1, 34.1, 92.8, 114.9, 128.4, 131.0, 147.3, 169.2; mass spectrum (ESIMS), $m/z = 349 (M+Na)^+$ C13H15BrN2NaOS requires 349; Anal. Calcd for C₁₃H₁₅BrN₂OS: C, 47.71; H, 4.62; N, 8.56. Found: C, 47.82; H, 4.44; N, 8.53.

Ethyl 2-(3-(2-Chloroethyl)ureido)-4,5,6,7-tetrahydrobenzo-[b]thiophene-3-carboxylate (5). A solution of ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 1a (1.125 g, 5.00 mmol) in toluene (5 mL) was treated with 2-chloroethyl isocyanate (0.636 mL, 7.50 mmol). The resulting solution was refluxed at 112 °C for 3 h under dry nitrogen. The solution was allowed to cool to room temperature and was then concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (75 mm \times 50 mm) eluting with 1:9 ethyl acetate-hexanes. The product was concentrated to dryness and crystallized from 2:2:6 dichloromethane-diethyl ether-hexanes): yield 867 mg (53%); $R_f = 0.56$ (3:7 ethyl acetate-hexanes); mp = 119-123 °C (Lit:⁵⁶ 123–125 °C); ¹H NMR (600 MHz, CDCl₃): δ 1.37-1.35 (t, J = 7.2 Hz, 3H), 1.78-1.77 (m, 4H), 2.60-2.58 (d, J = 6 Hz, 2H), 2.74-2.73 (d, J = 6 Hz, 2H), 3.68-3.65 (m, 2H)4H), 4.31-4.27 (q, J = 7.2, Hz, 2H), 5.52 (s, 1H); ¹³C NMR (600 MHz, CDCl₃): δ 14.4, 23.0, 24.4, 26.5, 42.5, 44.2, 60.4, 77.2, 109.4, 125.1, 130.6, 150.8, 153.7, 167.1; mass spectrum (ESIMS), $m/z = 332 (M+H)^+$, $C_{14}H_{20}ClN_2O_3S$ requires 332.

Methyl 5-O-p-Toluenesulfonyl- α -D-arabinofuranoside (6).²⁴ Methyl α -D-arabinofuranoside²⁴ (3.05 mmol) was dissolved in 20 mL of pyridine. Tosyl chloride was then added in slight excess (3.25 mmol) and the solution stirred at 37 °C for 24 h under dry nitrogen. The heat was removed and the reaction was allowed to progress at room temperature for an additional 5 days. Ice was used to quench the reaction and an additional 60 mL of water was added along with 15 mL of brine. The solution was extracted with ethyl acetate (3 × 35

mL). The organic layers were combined and back extracted with water and brine. Anhydrous sodium sulfate was used to dry the solution, which was then filtered and concentrated. The crude product was purified by flash column chromatography on silica gel (50 mm × 150 mm) eluting with 3:3:14 acetone– chloroform–hexanes (500 mL), followed by 1:1:3 acetone– chloroform–hexanes (250 mL), and finally followed by 1:1:2 acetone–chloroform–hexanes (200 mL). The product fractions were pooled and concentrated: yield 633 mg (65%); $R_f = 0.45$ (1:9 methanol–chloroform).

Methyl 5-O-p-Toluenesulfonyl-2,3-di-O-acetyl- α -D-arabinofuranoside (7)..^{57,58} Compound 7 (1.28 g, 3.88 mmol) was dissolved in 30 mL of 1:1 pyridine-acetic anhydride in a round-bottom flask. The solution was allowed to stir at room temperature under dry nitrogen for 24 h. The reaction was quenched with ice (30.0 g) and extracted using dichloromethane and back-extracted with brine. The solution was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel ($30 \text{ mm} \times 150 \text{ mm}$). The product was eluted with 1:3 ethyl acetate-hexanes, followed by 1:1 ethyl acetate-hexanes (100 mL). The product fractions were pooled and concentrated under reduced pressure: yield 1.15 g (73%); $R_f = 0.16$ (1:3 ethyl acetate-hexanes); ¹H NMR $(CDCl_{3}, 600 \text{ MHz}): \delta 2.08 (s, 6H), 2.45 (s, 3H), 3.36 (s, 3H),$ 4.16-4.18 (m, 1H), 4.26 (dd, 1H, J = 5.4, 10.8 Hz), 4.32 (dd, 1H, J = 3, 10.8 Hz), 4.87 (m, 1H), 4.89 (s, 1H), 5.02 (s, 1H), 7.35 (d, 2H, 6.6 Hz), 7.81 (d, 1H, J = 6.6 Hz); ¹³C NMR (600 MHz, CDCl₃): δ 20.9, 21.9, 55.6, 68.9, 71.4, 75.9, 78.8, 80.7, 81.1, 81.1, 107.0, 128.1, 128.2, 128.3, 130.1, 130.1, 133.0, 145.2, 170.1, 170.5, 170.7.

Methyl 2,3-Tri-O-acetyl-5-S-acetyl-5-thio- α -D-arabinofuranoside (8).²¹ Compound 7 (1.15 g, 2.86 mmol) was dissolved in 10 mL of anhydrous DMF in a round-bottom flask. An additional 10 mL of anhydrous DMF was used to dissolve KSCOCH₃ (0.40 g, 3.50 mmol). The KSCOCH₃ solution was then added dropwise to the starting material and allowed to stir at room temperature under nitrogen for 24 h. The solution was diluted with 50 mL of water and extracted with three 30 mL portions of ether. The ether layers were combined and washed with saturated sodium chloride solution. The ether was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel $(30 \text{ mm} \times 150 \text{ mm})$. The product was eluted with 1:1:5 acetone-chloroform-hexanes and concentrated to dryness under reduced pressure: yield = 525 mg (60%); $R_f = 0.39$ (2:3 ethyl acetate-hexanes); ¹H NMR (CDCl₃, 600 MHz): δ 2.03 (s, 6H), 2.33 (s, 3H), 3.12-3.17 (m, 1H), 3.32-3.37 (m, 4H), 4.14 (dd, 1H, J = 5.2, 12 Hz), 4.84 (s, 1H), 4.86 (d, 1H, J = 6.0), 4.98 (s, 1H). ¹³C NMR (600 MHz, CDCl₃): 21.0, 30.7, 31.3, 55.2, 78.2, 79.7, 81.9, 106.8, 170.0, 170.3, 194.9; mass spectrum (HRMS), m/z =329.0646 (M+Na)⁺, C₁₂H₁₈NaO₇S requires 329.0671.

Methyl α-*D*-*Arabinofuranoside-5-thiol* (9). A solution of 8 (3.37 g, 11.0 mmol) in 0.1 M methanolic NaOMe (40 mL) was stirred for 4 h at 50 °C under nitrogen and neutralized with Amberlite IR120 (H+ form). The resin was filtered off, and the filtrate was concentrated under reduced pressure. The residue was extracted with ethyl acetate to provide thiol 9 after concentration: yield 1.21 g (61%); ¹H NMR (CDCl₃, 600 MHz): δ 1.68–1.65 (t, ¹H, *J* = 6.0 Hz), 2.81–2.77 (m, 1H), 2.89–2.81 (m, 1H), 3.39 (s, 3H), 3.92–3.91 (m, 2H), 4.09–4.06 (m, 3H), 4.85 (s, 1H); ¹³C NMR (CDCl₃, 600 MHz): δ

26.9, 55.8, 79.9, 81.7, 84.4, 108.3; mass spectrum (HRMS), m/z = 203.0337 (M+Na)⁺, C₆H₁₂NaO₄S requires 203.0354.

5-lodo- α -D-arabinofuranoside (11). Methyl α -D-arabinofuranoside (10) (1.00 g, 6.66 mmol) was dissolved in dry THF (10 mL) and placed on ice. The reaction was cool to 0 °C in an ice bath and imidazole (1.07 g, 15.8 mmol), iodine (2.01 g, 7.92 mmol), and triphenylphosphine (2.00 g, 7.92 mmol) were added. The solution was warmed to 65 °C and allowed to stir for 1.5 h. The solution was diluted with 50 mL of water and extracted with dichloromethane $(3 \times 30 \text{ mL})$. The organic layers were combined, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel (30 mm \times 150 mm). The product was eluted with 8:1 chloroform-acetone and concentrated to dryness under reduced pressure: yield = 1.13 g (65%); $R_f = 0.50$ (3:1 chloroform-acetone); ¹H NMR (DMSO, 400 MHz) δ 3.25 (s, 2H), 3.35 (s, 3H), 3.46-3.59 (m, 2H), 3.83 (s, 1H), 4.64 (s, 1H), 5.39-5.40 (m,1H), 5.49-5.50 (m,1H); ¹³C NMR (DMSO, 100 MHz) δ 09.1, 54.5, 80.6, 81.2, 82.0, 108.8; mass spectrum (ESIMS), m/z = 297 (M+Na)⁺. Anal. Calcd for C₆H₁₁IO₄: C, 26.30; H, 4.05; N, 0.00; Found: C, 26.04; H, 4.02; N, 0.03.

Ethyl 2-(Methyl 5-thio- α -D-arabinofuranoside-5-S-yl)acetamido-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (13a). Step 1: Compound (2a) (0.100 g, 0.33 mmol) and thiourea (0.504 g, 0.66 mmol) were suspended in 2 mL of absolute ethanol and stirred for 3 h at 65 °C. The reaction was analyzed for completion by TLC 3:1 hexanes-ethyl acetate. The reaction was cooled and filtered. The filtrate was rinsed with absolute ethanol and concentrated to dryness under reduced pressure. Compound 12a was obtained as yellow color residue: yield 0.100 g (80%); mass spectrum (ESIMS), m/z =342 (M)⁺, C₁₄H₂₀N₃O₃S₂⁺ requires 342. Step 2: Compound (12a) (0.100 g, 0.29 mmol) was combined with compound 11 (0.040 g, 0.14 mmol), cesium carbonate (0.19 g, 0.584 mmol) in dry DMF (2 mL). The solution was stirred for 16 h at 85 °C under nitrogen atmosphere. The reaction was monitored by using TLC (2:1 toluene-acetone). On completion, the crude reaction mixture was loaded onto silica gel and the residual solvent evaporated under reduced pressure. The sample was loaded on silica gel column (30 mm \times 150 mm) and eluted with hexanes followed by 4:1 toluene-acetone to afford the product. The product fractions were combined, concentrated under reduced pressure. The product was pink amorphous solid: yield 0.018 g (28%); $R_f = 0.37$ (2:1 toluene-acetone); ¹H NMR (CDCl₃, 600 MHz); δ 1.39 (t, J = 7.2 Hz, 3H), 1.79 (m, 4H), 2.65 (m, 2H), 2.76 (m, 2H), 2.98 (m, 2H), 3.36 (s, OCH_3), 3.53 (d, J = 16.2 Hz, 1H), 3.64 (d, J = 16.2 Hz, 1H), 3.98 (m, 1H), 4.0 (m, 1H), 4.23 (m, 1H), 4.34 (q, J = 7.2 Hz, 2H), 4.89 (s, 1H). ¹³C NMR (CD₃OD, 400 MHz); δ 12.4, 20.2, 20.4, 20.6, 30.4, 30.6, 50.4, 60.0, 80.0, 80.2, 80.3, 100.9, 112.0, 126.0, 129.0, 146.0, 165.0,167.0; mass spectrum (HRMS), $m/z = 468.1089 \text{ (M+Na)}^+$, $C_{19}H_{27}NNaO_7S_2$ requires 468.1127.

N-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2-(methyl 5-thio- α -D-arabinofurano-side-5-S-yl)acetamide (**13b**). Step 1: Compound (**2c**) (0.200 g, 0.78 mmol) and thiourea (0.119 g, 1.57 mmol) were suspended in 4 mL absolute ethanol and stirred for 3 h at 65 °C. The reaction was analyzed for completion by TLC using 3:1 hexanes-ethyl acetate. The reaction was cooled and filtered. The filtrate was rinsed with a minimal amount of absolute ethanol and concentrated to dryness under reduced pressure. Compound 12b was obtained as brown color residue: yield 0.216 g (83%); mass spectrum (ESIMS), m/z = 295 (M)⁺, $C_{12}H_{15}N_4OS_2^+$ requires 295. Step 2: Compound 12b (0.118 g, 0.36 mmol) was combined with Compound 11 (0.05 mg, 0.18 mmol) and cesium carbonate (0.234 g, 0.72 mmol) in dry DMF (2 mL). The solution was stirred for 16 h at 85 °C under nitrogen atmosphere. The reaction was monitored in thin layer chromatography using (2:1 toluene-acetone). On completion, the crude reaction mixture was loaded onto silica gel and the residual solvent evaporated under reduced pressure. The sample was loaded on silica gel column ($30 \text{ mm} \times 150 \text{ mm}$) and eluted with hexanes followed by 4:1 toluene-acetone to afford the product. The product was orange amorphous solid: yield 0.040 g (56%); $R_f = 0.39$ (2:1 toulene-acetone); mp = 160–163 °C. ¹H NMR (CD₃OD, 600 MHz): δ 1.8 (m, 4H), 2.51 (m, 2H), 2.59 (m, 2H), 2.85 (dd, J = 24.6 Hz, 7.2 Hz, 1H), 2.93 (dd, J = 18.6 Hz, 4.2 Hz, 1H), 3.26 (s, OCH₃), 3.52 (d, J = 15 Hz, 1H), 3.54 (d, J = 15 Hz, 1H), 3.76 (m, 1H), 3.86 (m, 1H), 3.98 (m, 1H), 4.68 (d, J = 1.8 Hz, 1H). ¹³C NMR (CD₃OD, 400 MHz): δ 23.4, 24.3, 24.9, 25.1, 35.9, 36.5, 55.4, 81.7, 83.6, 84.5, 110.5, 114.9, 129.9, 132.6, 169.9; mass spectrum (HRMS), m/z = 421.0873 (M+Na)⁺, C₁₇H₂₂N₂O₅S₂ requires 421.0868.

Ethyl 2-(Methyl 5-thio- α -D-arabinofuranoside-5-S-yl)butamido-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (13c). Step 1: Compound 4a (0.275 g, 0.725 mmol) and thiourea (0.110 g, 1.45 mmol) were suspended in 2 mL of absolute ethanol and stirred at reflux for 4 h. The reaction was analyzed for completion by TLC using 3:1 hexanes-ethyl acetate. The reaction was cooled on ice and filtered. The filtrate was rinsed with a minimal amount of absolute ethanol and concentrated to dryness under reduced pressure. Compound 12c was obtained as colorless crystals. yield = 0.170 g (52%); mp = 212–213 °C; ¹H NMR (DMSO, 400 MHz) δ 1.25 (t, J = 7.2 Hz, 3H), 1.63 (br. s, 4H), 1.85-1.92 (m, 2H), 2.59-2.62 (m, 4H), 3.18 (t, J = 7.2 Hz, 2H), 3.37–3.41 (m, 1H), 4.22 (p, J = 6.8 Hz, 2H), 9.00–9.11 (m, 4H), 10.95 (s, 1H); ¹³C NMR (DMSO, 400 MHz) δ 14.1, 22.3, 22.5, 23.7, 24.3, 25.8, 29.4, 34.1, 60.3, 111.2, 125.9, 130.3, 145.9, 165.0, 168.9, 169.7; Anal. Calcd for C₁₆H₂₄BrN₃O₃S₂: C, 42.67; H, 5.37; N, 9.33; Found: C, 42.46; H, 5.17; N, 9.34. Step 2: Compound 12c was combined with compound 11 (0.110 g, 0.244 mmol) and cesium carbonate (0.268 g, 0.825 mmol) in dry DMF (4 mL). The solution was stirred for 16 h at 85 °C under nitrogen atmosphere. The reaction was monitored by TLC using (2:1 toluene-acetone). Upon completion, the crude reaction mixture was loaded onto silica gel and DMF was evaporated under reduced pressure. The dry slurry was purified by flash column chromatography on silica gel (30 mm × 150 mm). Elution with 4:1 toluene-acetone affords a partially purified product. The compound was further purified on a second silica gel column to remove residual DMF, eluting with (4:1 ethyl acetate-hexanes). The product fractions were combined, concentrated, and dried in vacuum where the product crystallized upon standing: yield = 0.080 g (77%); $R_f = 0.53$ (2:1 toulene-acetone); mp = 92-93 °C; ¹H NMR (CDCl₃, 400 MHz) δ 1.39 (t, J = 6.8 Hz, 3H), 1.78–1.79 (m, 4H), 2.04 (t, J = 7.2 Hz, 3H), 2.59–2.64 (m, 2H), 2.70–2.77 (m, 3H), 2.83-2.90 (m, 2H), 3.38 (s,3H), 3.90-3.93 (m,1H), 4.06 (d, J = 6.8 Hz, 1H), 4.20-4.22 (m, 1H), 4.34 (q, J = 7.2 Hz, 2H), 4.90 (s, 1H), 5.39 (d, J = 6.0 Hz, 1H), 11.32 (s, 1H) ppm; ¹³C NMR (CDCl₃, 400 MHz) δ 14.5, 23.0, 23.2, 24.5, 25.0, 26.6,

32.8, 34.5, 55.1, 60.8, 80.5, 80.7, 85.7, 109.1, 111.7, 127.0, 131.0, 147.5, 167.0, 169.4 ppm; mass spectrum (ESIMS), m/z = 496.2 (M+Na)⁺ Anal. Calcd for C₂₁H₃₁NO₇S₂: C, 53.26; H, 6.60; N, 2.96; O, 23.65; S, 13.54. Found: C, 53.32; H, 6.51; N, 2.93.

N-(3-Cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)-2- $(methyl-5-thio-\alpha-d-arabinofuranoside-5-S-yl)butamide$ (13d). Step 1: Compound 4b (0.300 g, 0.916 mmol) and thiourea (0.139g, 1.83 mmol) were suspended in 2 mL of absolute EtOH and stirred at reflux for 4 h. The reaction was analyzed for completion by using TLC 3:1 (hexanes-ethyl acetate). The reaction mixture was cooled on ice and filtered with minimal amount of abs EtOH and dried in vacuo. Compound 12d was obtained as colorless crystals: yield = 0.262 g (71%); mp = 205–207 °C. ¹H NMR (DMSO, 600 MHz): δ 1.67 (m, 4H), 1.83–1.85 (m, 3H), 2.01 (s, 2H), 2.40-2.44 (m, 2H), 2.55-2.58 (m, 2H), 3.12-3.132 (m, 2H), 8.98 (m, 1H) ppm; 13 C NMR (DMSO, 600 MHz): δ 21.7, 22.6, 23.3, 23.5, 24.0, 29.5, 30.7, 33.1, 114.3, 127.1, 130.6, 146.4, 169.6, 170.1 ppm; Anal. Calcd for C₁₄H₁₉BrN₄OS₂: C, 41.69; H, 4.75; Br, 19.81; N, 13.89; O, 3.97; S, 15.90. Found: C, 40.88; H, 4.57; N, 14.20. Step 2: Compound 12d was combined to compound 11 (0.210 g, 0.520 mmol), cesium carbonate (0.268 g, 0.825 mmol) were dissolved in dry DMF (5 mL). The solution was stirred for 24 h at 85 °C under nitrogen atmosphere. The reaction was monitored by thin layer chromatography using (1:1 acetone-hexanes). Upon completion, the crude reaction mixture was loaded onto silica gel and the DMF was evaporated under reduced pressure. The dry slurry was purified by flash column chromatography on silica gel (30 mm \times 150 mm). Elution was with 2:1 acetonehexanes. The product fractions were combined and concentrated to dryness. The crude product was crystallized using ethanol and filtered with cold ethanol: yield = 0.110 g (49%); R_{4} = 0.3 (1:1 acetone-hexanes); mp = 183-184 °C; ¹H NMR (DMSO, 600 MHz) δ 1.69 (s, 4H), 1.80 (p, J = 6.0 Hz, 4H), 2.42 (br. s, 2H), 2.51-2.62 (m, 4H), 2.73 (s, 1H), 3.18 (s, 3H), 3.56-3.58 (m, 1H), 3.71-3.72 (m, 1H), 3.74-3.76 (m, 1H), 4.55 (s, 1H), 5.25 (d, J = 6, 1H), 5.39 (d, J = 6.0 Hz, 1H), 11.51 (br. s, 1H) ppm; 13 C NMR (DMSO, 400 MHz) δ 21.8, 22.7, 23.3, 23.5, 24.8, 31.6, 33.8, 33.9, 54.4, 79.9, 80.1, 81.9, 82.6, 92.2, 109.0, 114.4, 127.04, 130.6, 146.67, 170.66 ppm; mass spectrum (HRMS), $m/z = 449.1199 (M+Na)^+$ C₁₉H₂₆N₂O₅S₂Na requires 449.1181; Anal. Calcd for C19H26N2O5S2: C, 53.50; H, 6.14; N, 6.57; O, 18.75; S, 15.03. Found: C, 48.78; H, 5.41; N, 3.71.

Methyl 5-S-[2-(2,4-Dioxo-1,4,5,6,7,8-hexahydro[1]benzothieno[2,3-d]-pyrimidin-3(2H)-yl)ethyl]-5-thioarabinofuranoside (14). Compound 10 (0.194 g, 0.634 mmol) and compound 5 (0.289 g, 0.868 mmol) were combined in 3 mL NaOMe (3.06 mmol Na metal in 3 mL NaOH). The solution was stirred at room temperature for 24 h then quenched using 20 mL 1 N HCl. The solution was diluted with water and extracted with chloroform $(3 \times 20 \text{ mL})$. The chloroform was dried with anhydrous sodium sulfate, filtered, and dried under reduced pressure. The product was purified by flash column chromatography on silica gel $(30 \text{ mm} \times 150 \text{ mm})$ eluting with 50:50 hexanes-acetone. The product fractions were concentrated to afford 14, a colorless waxy solid: yield = 36 mg (13%); $R_f = 0.46$ (1:1 hexanes-acetone); ¹H NMR (CDCl₃, 600 MHz): δ 1.78 (m, 4H), 2.60 (s, 2H), 2.83-3.04 (m, 6H), 3.37 (s, 3H), 4.03 (br. s, 2H), 4.13 (br. s, 1H), 4.19 (m, 4H), 4.88 (s, 1H), 10.91 (br. s, 1H); ¹³C NMR (CDCl₃, 600 MHz): δ 22.2,

23.2, 24.7, 25.5, 30.3, 34.3, 39.8, 55.4, 80.0, 81.5, 83.9, 108.8, 114.0, 127.3, 132.2, 148.7, 152.2, 159.1; mass spectrum (HRMS), m/z = 451.0969 (M+Na)⁺, $C_{18}H_{25}N_2O_6S_2$ requires 429.1154.

RESULTS AND DISCUSSION

Molecular Modeling. The substrate analogues shown in Figure 2 all contain the 2-amino-4,5,6,7-tetrahydrobenzo [b]thiophene scaffold. Different linker lengths and the arabinose moiety were converted to three-dimensional structures (MDL mol file format) using Chem3D (CambridgeSoft). The compound data sets were then imported into Maestro v 8.0 (Schrodinger, Inc.) and were prepared for docking using MacroModel (Schrodinger, Inc.) by using conformational analysis and minimization methods to obtain the lowest energy conformer. The crystallographic coordinates for the Ag85Coctylthioglucoside complex (PDB code: 1va5)²⁹ was obtained from the Protein Data Bank (www.rcsb.org) and prepared by removing all the solvent and adding hydrogen atoms and minimal minimization in the presence of bound ligand using protein preparation. Grids for molecular docking with Glide v 4.5 (Schrodinger, Inc.) were calculated without any constraint to the protein.⁵⁹ Compounds were docked using *Glide* in extraprecision mode, with up to five poses saved per molecule. The docked poses were then minimized using the local optimization feature in MacroModel,⁶⁰ and the energies were calculated using the OPLS force field⁶¹ and the GBSA continuum model⁶² in *Maestro*. The binding free energy ΔG_{bind} is estimated as

 $\Delta G_{\rm bind} = \Delta E_{\rm MM} + \Delta G_{\rm solv} + \Delta G_{\rm SA}$

where $\Delta E_{\rm MM}$ is the difference in energy between the complex structure and the sum of the energies of the ligand and the unliganded protein, using the OPLS force field, ΔG_{solv} is the difference in the GBSA solvation energy of the complex and the sum of the solvation energies for the ligand and unliganded protein, and ΔG_{SA} is the difference in the surface area energy for the complex and the sum of the surface area energies for the ligand and uncomplexed protein. Corrections for entropic changes were not applied. Finally, according to the docking score and binding energy we selected the candidate structures for preparing and testing as inhibitors for Ag85C. Structures with good docking scores included compounds containing a 2amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonitrile or an ethyl 2-amino-4,5,6,7-tetrahydro-3-carboxylate linked through the 2-amino moiety to a methyl 5-thio- α -D-arabinofuranoside. The docking scores are shown in Table 1 and include 13a-d and compound 14. Of these compounds, 13a showed the highest binding energy of -62 kJ/mol.

Potential intermolecular hydrogen-bonded interactions between compound 13a and the Ag85C protein showed four

Table 1. Docking Scores, Binding Energies, and Measured K_i of Compounds 13a-d and Compound 14

compound	docking score	binding energy	$K_{\rm i} \ (\mu {\rm M})^a$
native ligand	-11.3	-53	N.D.
13a	-12	-62	18.2 ± 1.8
13b	-12.88	-19	34.8 ± 3.8
13c	-11.4	-6	71.0 ± 5.3
13d	-10.9	-29	N.D.
14	-11.85	-15	47.1 ± 3.9

 a N.D. = no data.

Table 2. X-ray Diffraction and Crystallographic Refinement Data

diffraction statistics				
resolution range (å) (highest shell)	35-2.15 (2.20-2.15)			
space group	P2 ₁ 2 ₁ 2 ₁			
unit cell parameters	$a=67.5, b=80.2, c=136.6, \alpha=\beta=\gamma=90^\circ$			
total reflections (unique reflections)	246 157 (40 674)			
completeness (%) (highest shell)	99.0 (99.9)			
average $I/\sigma I$	7.0			
R _{sym} (%) (highest shell)	8.8 (40.4)			
refinement statistics				
protein molecules/atoms (per A.S.U.)		2/4695		
$R_{\rm work}/R_{\rm free}$ (%)	15.86/19.66			
average B-factor (Ų) (protein/l	igand/solvent)	25.66/43.58/36.17		
ligand occupancy (%)		100		
r.m.s.d. bonds/angles (Å/°)		0.007/1.041		
Ramachanran (favored/disallowe	ed) (%)	96.2/0.0		

hydrogen bonds (OH-3 of the arabinose with NH of Arg41 and HOH 2037, OH-4 of the arabinose with NH of Trp262, and S of the linker with HOH 2242) (Figure 3). In addition, the



Figure 3. Hypothetical binding mode of inhibitor **13a** in the Ag85C active site predicted using *Glide 4.5*. The arabinofuranoside substituent is located in the trehalose binding pocket, and the ester moiety is oriented in the vicinity of Ser124. The tetrahydrobenzo[*b*]thiophene is accommodated in the mycolate α -chain binding channel extending through the core of Ag85C.

calculated distance between the OH of Ser124 and the carbon of carbonyl carbon of the ester was found to be 6.876 Å. Finally, we calculated the electrostatic interactions between compound **13a** and the Ag8SC protein (Figure 4). According to the hydrogen bond and electrostatic interactions, compound **13a** was expected to be a good template for occupying the active site of the enzyme.

Synthesis of Glycoconjugates. Both the 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carbonitrile and ethyl 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate classes of thiophenes could be accessed through a classic Gewald synthesis⁵² followed by amine functionalization with an appropriate linker. The Gewald synthesis was performed by treating cyclohexanone with malononitrile or ethyl cyanoace-tate and sulfur in the presence of *N*-ethylmorpholine to yield 3-carboxylate thiophene $1a^{51}$ and 3-carbonitrile thiophene 1b, respectively, in a modest yield. Thiophenes 1a and 1b were then reacted with either chloroacetyl chloride or 4-chlorobutyrl chloride to prepare amides 2a-d (Scheme 1) in modest yield.

Alternatively, 1a was reacted with 2-chloroethyl isocyanate to form urea 5^{56} in 53% yield. With key intermediates in hand, we explored different approaches to form a thioether linkage between the thiophenes and the C-5 position of a methyl α -Darabinofuranoside. In the first approach, the chloro substituent of thiophenes 2a-d was displaced with potassium thioacetate in anhydrous DMF to afford the thioesters 3a-d in yields of 62-92%. The resulting thiophenes were treated with NaOEt, concentrated, and directly reacted with the known methyl 5-O*p*-toluenesulfonyl- α -D-arabinofuranoside (6) (Scheme 3).^{24–26} Unfortunately, we failed to isolate an identifiable product using this protocol. We then chose to reverse the polarity of the electrophile by converting the tosylate to a sulfhydryl. This required peracetylation of arabinofuranoside 6 with acetic anhydride to afford the diacetylated compound 7 in 73% yield (Scheme 2). Acetylated sulfonate 7 was then treated with potassium thioacetate to afford the thioester 8 in 60% yield. Arabinofuranoside 8 was then treated with NaOMe at 50 °C for 2 h. The reaction was neutralized with Amberlite IR120 (H + form), filtered and dried. The resulting methyl 5-deoxy-5thio- α -D-arabinofuranoside 9 was resuspended in THF and combined with an equivalent of alkyl chlorides 2a-d and triethyl amine to afford glycoconjugates 13a-d (Scheme 3). In our hands, only the α -chloroamides **2a** and **2c** reacted with the mercaptan 9 to produce thioethers 13a and 13b, respectively, in unacceptable yield. Modification of bases and solvents and addition of disulfide reducing agents failed to generate the longer-chain thioethers.

Unsatisfied with failure of the reaction between halides **2b** and **2d** and mercaptan **9**, as well as poor coupling yields to this point, we began to explore alternate options for synthesizing the desired thioether linkages. There are numerous examples of alkyl halides reacting with isothiourionium salts to form thioethers.⁶³ Therefore, we converted methyl α -D-arabinofuranoside (**10**)^{24–26} to the known methyl 5-deoxy-5-iodo- α -D-arabinofuranoside (**11**) using I₂-P(Ph)₃-imidizole in 65% yield (Scheme 2).⁶⁴ Compounds **1a** and **1b** were then acylated with 4-chlorobutyryl chloride to provide amides **4a** and **4b**, respectively (Scheme 1). Amides **2a**, **2c**, **4a**, and **4b** were then treated with thiourea in refluxing ethanol to afford the respective isothiourionium salts **12a**–**d**, in good yield (Scheme 3). The isothiourionium salts reacted cleanly with iodide **11** in the presence of cesium carbonate in *N*,*N*-dimethylformamide to form thioethers **13a**–**d**, respectively.

We also found it noteworthy that chloride **5** and methyl 5thio- α -D-arabinofuranoside **8** in methanol-NaOMe, afforded the 3-substituted pyrimidinedione **14** linked to a methyl 5-thio- α -Darabinofuranoside moiety (Scheme 4). The resulting materials were then used to evaluate the structural class as inhibitors of the Ag85C acyltransferase activity.

Enzyme Inhibition Studies. To determine if any compounds from this library inhibit the Ag85C enzyme, assays measuring the enzymatic activity were performed. These assays employed 4-methylumbelliferyl butyrate (4MUB) as the acyl donor and trehalose as the acyl acceptor. Binding of 4MUB within the enzyme active site allows nucleophilic attack on the substrate to produce an acyl-Ag85C intermediate and release of the fluorescent molecule 4-methylumbelliferone (4-MU). Subsequent binding of trehalose in the active site allows nucleophilic attack by trehalose on the acyl-Ag85C intermediate to form trehalose-6-butyrate. Measuring the fluorescence emission of 4-MU at 500 nm affords an accurate determination of the initial rate of the enzymatic reaction.



Figure 4. Electrostatic potential and hydrogen bonding interaction between compound 13a and Ag85C. The distances between the OH of Ser124 and the ester and amide C=O moieties of 13a is indicated by green lines.



¹⁰ ⁴Reagent and conditions: (i) Ac₂O, pyridine, 24 h, rt (73%); (ii) KSCOCH₃, DMF, 24 h, rt (60%); (iii) 0.1 M methanolic NaOMe 2 h, 50 °C then Amberlite IR120; (iv) imidazole, I₂, PPh₃, THF, 0 to 65

°C, (65%).

To determine the K_i values for the library of inhibitors, the initial reaction rate using this fluorescence-based assay was performed in the presence of varying concentrations of each inhibitor. The ratio of the rates of the inhibited reaction versus the uninhibited reaction plotted as a function of inhibitor concentration exhibits a clear dose-dependent decrease in enzymatic activity. Fitting these data allowed the calculation of K_i values for each of the inhibitors, which ranged from 18.2 to 71.0 μ M (Table 1 and Figure 5A).

While the K_i values of the inhibitors do not vary significantly, a general trend is observed that offers insight for the design of second-generation compounds with improved affinity for the Ag85C enzyme and better inhibitory activity. Because of the choices of arabinofuranosides tested, the importance of two structural variables can be related to inhibitory activity. First, of the thiophene containing compounds, those elaborated with the ethyl ester moiety on the thiophene, have slightly better inhibitory activity than compounds with a corresponding nitrile moiety as seen when comparing the K_i values of 13a and 13b.

Scheme 3. Isothiourionium Salt-Based Synthesis of Thioethers $\!\!\!\!\!^a$



^aReagent and conditions: (i) NaOEt, MeOH, rt, no reaction; (ii) THF, TEA, 6 h, rt, no reaction; (iii) $CS(NH_2)_2$, EtOH, 4 h, reflux, **12a** (83%), **12b** (80%), **12c** (52%), **12d** (71%); (iv) **12a–12d**, Cs₂CO₃, DMF, 16 h, 85 °C, **13a** (28%), **13b** (56%), **13c** (77%), **13d** (49%).

Scheme 4. Synthesis of Pyrimidinedione 14^{a}



^aReagents and conditions: (i) NaOMe, MeOH, 24 h, rt (13%).



Figure 5. Inhibition of Ag85C. (A) v_i' represents the initial velocity of the inhibited enzymatic reaction at the respective inhibitor concentration. v_i represents the initial velocity of the uninhibited enzymatic reaction. (B) The enzyme active site is shown (with green carbon atoms) with one molecule of **13a**, one water molecule, and two molecules of glycerol (molecules with gray carbon atoms). The placement of these compounds was based on the F_o - F_c omit maps (light blue difference density) shown contoured at 3σ . Colors for the atoms other than carbon are blue, red, and yellow for nitrogen, oxygen, and sulfur, respectively.

Second, the length of the linker between the thioether and the aromatic fused ring system affects inhibitory activity. Compound 13a, which contains a methylene linker, exhibits stronger inhibition than 13c, which possesses a propylene linker. The

single three-ringed compound tested is difficult to analyze in isolation. The K_i is near the middle of the range observed in the inhibition studies. Synthesis of similar compounds and further testing will be required to determine if there is a benefit to having the third ring. The compounds were screened for growth inhibition activity against *M. smegmatis*; however, no growth inhibition was observed.

Crystal Structure of the Ag85C-Inhibitor Complex. To gain insight into the mechanism of inhibition and information necessary to develop better inhibitors, specific structural information is needed. To this end, crystals of recombinant Ag85C were soaked with compound **13a**. Compound **13a** was chosen because it possesses the lowest K_i value. The difference map calculated with these data show four strong regions of electron density within the Ag85C active site. These are consistent with one compound of **13a**, a single water molecule, and two molecules of glycerol. The binding of **13a** within the active site indicates that it functions as a competitive inhibitor of Ag85C (Figure SB).

The orientation of **13a** within the active site of the crystal structure (Figure 6) is different with respect to the predicted structure from the inhibitor modeling data. The thiophene moiety is positioned in roughly the same location, but is flipped 180° along the major axis of the two-ringed system to position the ethyl ester pointing away from the enzyme rather than into the hydrophobic tunnel. The arabinofuranoside moiety binds within the known carbohydrate-binding site as exhibited for the Ag85B-trehalose crystal structure.³⁰ However, the arabinosyl moiety of **13a** overlaps with the glucosyl moiety of trehalose that is distal to Ser124 of Ag85B rather than binding in the proximal carbohydrate binding pocket that accommodates the sugar to be acylated by the enzyme.

Unexpectedly, no specific hydrogen bonding interactions are being formed between the arabinofuranoside and the carbohydrate-binding site of the active site. This would suggest that the binding is driven by hydrophobic interactions between the thiophene moiety and the mycolyl binding site, and that linker length as well as shape complementarity between the arabinosyl moiety and the carbohydrate binding site ultimately



Figure 6. Interactions between 13a and the Ag85C active site. Two views of the Ag85C active site are shown from different orientations. (A) Nonspecific interactions. The Ag85C protein backbone is shown as the green ribbon. The carbon atoms are in green, nitrogen atoms are in blue, oxygen in red, and sulfur in yellow. The location of the serine nucleophile is shown as a reference. All of the hydrophobic residues within 4 Å of the thiophene moiety are shown, as well as the R41 side chain that interacts with the thioether linker. (B) The superposition of the trehalose-bound Ag85B and the 13a-bound Ag85C structures shows overlap of the trehalose and 13a binding sites. The trehalose from the Ag85B structure is shown with gray carbon atoms. All other atom types are colored as in panel A. The distal glucosyl moiety of trehalose and the methylarabinoside of 13a are clearly occupying the same region within the active site. The proximal glucosyl and an ordered glycerol molecule also superimpose well and form similar hydrogen bonding interactions with Ag85. The ordered water molecule near O6 of the Ag85b-bound trehalose is shown. The dashed lines represent hydrogen bonds between this water molecule and the 13a amide carbonyl, the side chain of Ser124, and the backbone amide of Leu40, which forms part of the oxyanion hole. The length of these hydrogen bonds range from 2.6 to 3.0 Å.

Bioconjugate Chemistry

determine the location of the arabinosyl binding. The interaction between Ag85C and the arabinofuranosyl moiety is rather dissimilar to the interactions observed in the Ag85B-trehalose crystal structure, where O2 and O3 of the distal glucosyl moiety of trehalose are hydrogen-bonded to the side chain of Arg41 and O6 is hydrogen-bonded to the backbone carbonyl of His260.³⁰

The fused, two-ring system of 13a is positioned in the proposed mycolic acid-binding pocket and forms van der Waals interactions with the side chains of Phe150, Trp158, Leu161, Ala165, and Leu227.^{29,33} In addition, the linker connecting the thiophene to the arabinofuranosides moiety forms van der Waals interactions with the side chain of Arg41. The carbonyl oxygen of the amide moiety appears to be poised to form a hydrogen bond with the backbone amide of Leu40, although the 4.5 Å distance between these is too long for a bonafide hydrogen bond. The approach of 13a to the oxyanion hole is blocked by an ordered water molecule that forms hydrogen bonds with both the oxyanion hole and the amide carbonyl of 13a. One key to improving binding and inhibitory activity of a second-generation inhibitor would be to displace this water molecule with a hydrogen bond acceptor to promote a direct interaction between the inhibitor and the oxyanion hole.

Another important piece of information from this structure can be used for future design efforts to improve both strength and specificity of binding. The pocket initially assumed to be important for binding the trehalose still has an undefined role.³³ To date, no structure has revealed binding of any substrate or product analogues within this site even though the residues forming this site (Asp38, Asp45, and Trp262) are conserved in all Ag85 complex mycolyltransferases. The only compounds observed in any structures within this site are glycerol and water, which implies that it may accommodate additional carbohydrate moieties exposed on the surface of the mycobacterial outer membrane.^{28,29,33} One potential substrate accommodated by this conserved site would be a neighboring subunit of the arabinan. As the conserved sequence and structure in this region implies an important role, the Ag85C-13a complex structure gives very specific information regarding the future design of inhibitors that could bind within this site. Specifically, the methyl group on the methyl-arabinofuranoside can be replaced with a much bulkier moiety such as another arabinofuranosyl moiety, capable of forming a complex hydrogen-bonded network with the conserved residues in this site. Alternatives other than carbohydrates could also be used. Ideally, these groups would possess a large number of both hydrogen bond donors and acceptors to maximize the interaction potential within this site.

CONCLUSION

Virtual thiophene–arabinoside conjugates were docked to antigen Ag85C using *Glide*. Compounds with good docking scores were synthesized by a Gewald synthesis followed by linking to 5-thioarabinofuranosides. The resulting thiophenylthioarabinofuranosides were assayed for inhibition of mycoyltransferase activity using a 4-methylumbelliferyl butyrate fluorescence assay. The conjugates showed K_i values that ranged from 18.2 to 71.0 μ M. The inhibitor with the lowest K_i value, **13a**, was used to obtain a crystal structure of the inhibitor bound within the active site of Ag85C. Closely related thiophene derivatives have recently been shown to inhibit the synthesis of TDM, a mycobacterial virulence factor, and inhibit the growth of *M. tuberculosis* particularly in macrophages. The limited set of structures we identified showed no activity against *M. smegmatis*, a model organism, in a disk diffusion assay; however, the structures we identified are very similar to thiophenes which show activity in macrophages infected with drug resistant strains *M. tuberculosis*. On the basis of this observation, we plan to evaluate these compounds and others in a macrophage infection model. The crystal structure highlights interactions between both the thiophene and arabinofuranosides moieties and will be leveraged to design improved inhibitors of Ag85s.

ASSOCIATED CONTENT

Supporting Information

¹H and ¹³C spectra for compounds 2a-2d, 3a-3d, 4a, 4b, 5, 7-9, 11, 12c, 12d, 13a-d, 14, HRMS for compound 14. The material is available free of charge via Internet at http://pubs. acs.org.

AUTHOR INFORMATION

Corresponding Author

*S.J.S.: phone, 419-530-1054; fax, 419-530-1190; e-mail, steve. sucheck@utoledo.edu. D.R.R.: phone, 419-530-1585; e-mail, donald.ronning@utoledo.edu.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor for the support of this research program (Grant 085P1000817). This was supported by an NIH grants to D. R. Ronning (AI089653) and S. J. Sucheck (GM094734). We also thank students Shen Zhang and Shuangqianzi Li for assistance with the resynthesis and characterization of key intermediates.

REFERENCES

(1) Institute of Medicine of the National Academies (2009) Addressing the Threat of Drug-Resistant Tuberculosis: A Realistic Assessment of the Challenge. Workshop Summary, The National Academies Press, Washington, DC.

(2) Zhang, Y., and Amzel, L. M. (2002) Tuberculosis drug targets. *Curr. Drug Targets* 3, 131–54.

(3) Chatterjee, D., and Brennan, P. J. (2009) Glycosylated Components of the Mycobacterial Cell Wall: Structure and Function, In *Microbial Glycobiology* (Moran, A. P., Ed) pp 147–167, Elsevier, London.

(4) Brennan, P. J., and Nikaido, H. (1995) The envelope of mycobacteria. *Annu. Rev. Biochem.* 64, 29-63.

(5) Belanger, A. E., Besra, G. S., Ford, M. E., Mikusova, K., Belisle, J. T., Brennan, P. J., and Inamine, J. M. (1996) The *embAB* genes of *Mycobacterium avium* encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. *Proc. Natl. Acad. Sci. U.S.A.* 93, 11919–11924.

(6) Telenti, A., Philipp, W. J., Sreevatsan, S., Bernasconi, C., Stockbauer, K. E., Wieles, B., Musser, J. M., and Jacobs, W. R., Jr. (1997) The *emb* operon, a gene cluster of *Mycobacterium tuberculosis* involved in resistance to ethambutol. *Nat. Med.* 3, 567–570.

(7) Takayama, K., Wang, L., and David, H. L. (1972) Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and

viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2, 29–35.

(8) Schroeder, E. K., de Souza, O. N., Santos, D. S., Blanchard, J. S., and Basso, L. A. (2002) Drugs that inhibit mycolic acid biosynthesis in *Mycobacterium tuberculosis. Curr. Pharm. Biotechnol.* 3, 197–225.

(9) Takayama, K., Wang, C., and Besra, G. S. (2005) Pathway to synthesis and processing of mycolic acids in *Mycobacterium tuberculosis*. *Clin. Microbiol. Rev.* 18, 81–101.

(10) Fukui, Y., Hirai, T., Uchida, T., and Yoneda, M. (1965) Extracellular proteins of tubercle bacilli. IV. Alpha and beta antigens as major extracellular protein products and as cellular components of a strain (H37Rv) of *Mycobacterium tuberculosis. Biken J. 8*, 189–199.

(11) Kilburn, J. O., Takayama, K., and Armstrong, E. L. (1982) Synthesis of trehalose dimycolate (cord factor) by a cell-free system of *Mycobacterium smegmatis. Biochem. Biophys. Res. Commun.* 108, 132–139.

(12) Sathyamoorthy, N., and Takayama, K. (1987) Purification and characterization of a novel mycolic acid exchange enzyme from *Mycobacterium tuberculosis. J. Biol. Chem.* 262, 13417–13423.

(13) Jackson, M., Raynaud, C., Lanéelle, M.-A., Guilhot, C., Laurent-Winter, C., Ensergueix, D., Gicquel, B., and Daffé, M. (1999) Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the *Mycobacterium tuberculosis* cell envelop. *Mol. Microbiol.* 31, 1573–1587.

(14) Puech, V., Bayan, N., Salim, K., Leblon, G., and Daffé, M. (2000) Characterization of the in vivo acceptors of the mycologl residues transferred by the corynebacterial PS1 and the related mycobacterial antigens 85. *Mol. Microbiol.* 35, 1026–1041.

(15) Belisle, J. T., Vissa, V. D., Sievert, T., Takayama, K., Brennan, P. J., and Besra, G. S. (1997) Role of the major antigen of *Mycobacterium tuberculosis* in cell wall biogenesis. *Science* 276, 1420–1422.

(16) Harth, G., Horwitz, M. A., Tabatadze, D., and Zamecnik, P. C. (2002) Targeting the *Mycobacterium tuberculosis* 30/32 kDa mycolyl transferase complex as a therapeutic strategy against tuberculosis: Proof of principle using antisense technology. *Proc. Natl. Acad. Sci.* U.S.A. 99, 15614–15619.

(17) Harth, G., Zamecnik, P. C., Tabatadze, D., Pierson, K., and Horwitz, M. A. (2007) Hairpin extensions enhance the efficacy of mycolyl transferase-specific antisense oligonucleotides targeting *Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U.S.A.* 104, 7199–204.

(18) Nguyen, L., and Pieters, J. (2009) Mycobacterial subversion of chemotherapeutic reagents and host defense tactics: challenges in tuberculosis drug development. *Annu. Rev. Pharmacol. Toxicol.* 49, 427–53.

(19) Gobec, S., Plantan, I., Mravljak, J., Ŝavajger, U., Wilson, R. A., Besra, G. S., Soares, S. L., Appelberg, R., and Kikelj, D. (2007) Design, synthesis, biochemical evaluation and antimycobacterial action of phosphonate inhibitors of antigen 85C, a crucial enzyme involved in biosynthesis of the mycobacterial cell wall. *Eur. J. Med. Chem.* 42, 54– 63.

(20) Kremer, L., Maughan, W. N., Wilson, R. A., Dover, L. G., and Besra, G. S. (2002) The *M. tuberculosis* antigen 85 complex and mycolyltransferase activity. *Lett. Appl. Microbiol.* 34, 233–237.

(21) Wang, J., Elchert, B., Hui, Y., Takemoto, J. Y., Bensaci, M., Wennergren, J., Chang, H., Rai, R., and Chang, C.-W. T. (2004) Synthesis of trehalose-based compounds and study of their antibacterial activity against *Mycobacterium smegmatis*. *Bioorg. Med. Chem.* 12, 6397–6413.

(22) Rose, J. D., Maddry, J. A., Comber, R. N., Suling, W. J., Wilson, L. N., and Reynolds, R. C. (2002) Synthesis and biological evaluation of trehalose analogs as potential inhibitors of mycobacterial cell wall biosynthesis. *Carbohydr. Res.* 337, 105–120.

(23) Barry, C. S., Backus, K. M., Barry, C. E., III, and Davis, B. G. (2011) ESI-MS Assay of *M. tuberculosis* cell wall Antigen 85 enzymes permits substrate profiling and design of a mechanism-based inhibitor. *J. Am. Chem. Soc.* 133, 13232–13235.

(24) Kam, B. L., Barascut, J.-L., and Imbach, J.-L. (1979) A general method of synthesis and isolation, and an NMR spectroscopic study, of tetra-O-acetyl-D-aldopentofuranose. *Carbohydr. Res.* 69, 135–142.

(25) Ayers, J. D., Lowary, T. L., Morehouse, C. B., and Besra, G. S. (1998) Synthetic arabinofuranosyl oligosaccharides as mycobacterial arabinosyltransferase substrates. *Bioorg. Med. Chem. Lett.* 8, 437–442.

(26) Sanki, A. K., Boucau, J., Srivastava, P., Adams, S. S., Ronning, D. R., and Sucheck, S. J. (2008) Synthesis of methyl 5-S-alkyl-5-thioarabinofuranosides and evaluation of their antimycobacterial activity. *Bioorg. Med. Chem.* 16, 5672–5682.

(27) Boucau, J., Sanki, A. K., Voss, B. J., Sucheck, S. J., and Ronning, D. R. (2009) A coupled assay measuring *Mycobacterium tuberculosis* antigen 85C enzymatic activity. *Anal. Biochem.* 385, 120–127.

(28) Sanki, A. K., Boucau, J., Umesiri, F. E., Ronning, D. R., and Sucheck, S. J. (2009) Design, synthesis and biological evaluation of sugar-derived esters, alpha-ketoesters and alpha-ketoamides as inhibitors for Mycobacterium tuberculosis antigen 85C. *Mol. BioSyst. 5*, 945–956.

(29) Ronning, D. R., Vissa, V., Besra, G. S., Belisle, J. T., and Sacchettini, J. C. (2004) *Mycobacterium tuberculosis* antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity. *J. Biol. Chem.* 279, 36771–36777.

(30) Anderson, D. H., Harth, G., Horwitz, M. A., and Eisenberg, D. (2001) An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the *Mycobacterium tuberculosis* 30 kDa major secretory protein (Antigen 85B), a mycolyl transferase. *J. Mol. Biol.* 307, 671–681.

(31) Goulding, C. W., Perry, L. J., Anderson, D., Sawaya, M. R., Cascio, D., Apostol, M. I., Chan, S., Parseghian, A., Wang, S.-S., Wu, Y., Cassano, V., Gill, H. S., and Eisenberg, D. (2003) Structural genomics of *Mycobacterium tuberculosis*: a preliminary report of progress at UCLA. *Biophys. Chem.* 105, 361–370.

(32) Tonge, P. J. (2000) Another brick in the wall. *Nat. Struct. Biol.* 7, 94–96.

(33) Ronning, D. R., Klabunde, T., Besra, G. S., Vissa, V. D., Belisle, J. T., and Sacchettini, J. C. (2000) Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. *Nat. Struct. Biol.* 7, 141–146.

(34) Sanki, A. K., Boucau, J., Ronning, D. R., and Sucheck, S. J. (2009) Antigen 85C-mediated acyl transfer between synthetic acyl donors and fragments of the arabinan. *Glycoconj. J. 5*, 589–596.

(35) Umesiri, F. E., Sanki, A. K., Boucau, J., Ronning, D. R., and Sucheck, S. J. (2010) Recent advances toward the inhibition of mAG and LAM synthesis in *Mycobacterium tuberculosis. Med. Res. Rev.* 30, 290–326.

(36) Amemiya, Y., Terada, A., Wachi, K., Miyazawa, H., Hatakeyama, N., Matsuda, K., and Oshima, T. (1989) Synthesis and thromboxane synthetase inhibitory activity of di- or tetrahydrobenzo[b]-thiophenecarboxylic acid derivatives. J. Med. Chem. 32, 1265–1272.

(37) Bilokin, Y. V., Vasylyev, M. V., Branytska, O. V., Kovalenko, S. M., and Chernykh, V. P. (1999) A novel and expedient approach to new heterocycles containing benzothiophene, benzothieno[2,3-d]-pyrimidine and coumarin moieties. *Tetrahedron* 55, 13757–13766.

(38) Baraldi, P. G., Romagnoli, R., Pavani, M. G., Nunez, M. C., Tabrizi, M. Ag., Shryock, J. C., Leung, E., Moorman, A. R., Uluoglu, C., Iannotta, V., Merighi, S., and Borea, P. A. (2003) Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A₁ adenosine receptor. *J. Med. Chem.* 46, 794–809. (39) Bishop, A. C., and Blair, E. R. (2006) A gatekeeper residue for

inhibitor sensitization of protein tyrosine phosphatases. Bioorg. Med. Chem. Lett. 16, 4002–4006.

(40) Kaila, N., Janz, K., Huang, A., Moretto, A., DeBernardo, S., Bedard, P. W., Tam, S., Clerin, V., Keith, J. C., Jr., Tsao, D. H. H., Sushkova, N., Shaw, G. D., Camphausen, R. T., Schaub, R. G., and Wang, Q. (2007) 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): Identification of a clinical candidate from the quinoline salicylic acid series of Pselectin antagonists. J. Med. Chem. 50, 40–64.

(41) Sanki, A. K., Sucheck, S. J., Ronning, D. R., Boucau, J., Umesiri, F. E., and Ibrahim, D. A. (2010) Inhibitors of Antigen 85 from Mycobacterium tuberculosis, *Abstracts of Papers, 239th ACS National Meeting*, March 21–25, San Francisco, CA, United States, ORGN-118.

(42) Ibrahim, D. A., Adams, S. S., Sucheck, S. J., Trabbic, K. R., Ronning, D. R., Sanki, A. K., and Boucau, J. (2010) Inhibitors of *Mycobacterium tuberculosis* Antigen 85, *Abstracts, 41st Central Regional Meeting of the ACS*, June 16–19, Dayton, OH, United States, CERMACS-307.

(43) Scheich, C., Puetter, V., and Schade, M. (2010) Novel small molecule inhibitors of MDR *Mycobacterium tuberculosis* by NMR fragment screening of antigen 85C. J. Med. Chem. 53, 8362–8367.

(44) Warrier, T., Tropis, M., Werngren, J., Diehl, A., Gengenbacher, M., Schlegel, B., Schade, M., Oschkinat, H., Daffe, M., Hoffner, S., Eddine, A. N., and Kaufmann, S. H. E. (2012) Antigen 85C inhibition restricts *Mycobacterium tuberculosis* growth through disruption of Cord Factor biosynthesis. *Antimicrob. Agents Chemother.* 56, 1735–1743.

(45) Otwinowski, Z., and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode. *Methods Enzymol.* 276, 307–26.

(46) Kissinger, C. R., Gehlhaar, D. K., and Fogel, D. B. (1999) Rapid automated molecular replacement by evolutionary search. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 55, 484–91.

(47) Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. *Acta Crystallogr., Sect. D: Biol. Crystallogr. 66*, 486–501.

(48) Adams, P. D., Gopal, K., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Pai, R. K., Read, R. J., Romo, T. D., Sacchettini, J. C., Sauter, N. K., Storoni, L. C., and Terwilliger, T. C. (2004) Recent developments in the PHENIX software for automated crystallographic structure determination. *J. Synchrotron Radiat.* 11, 53–5.

(49) Adams, P. D., Grosse-Kunstleve, R. W., Hung, L. W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., and Terwilliger, T. C. (2002) PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* 58, 1948–54.

(50) National Committee for Clinical Laboratory Standards (2000) Approved Standard: M2-A7, *Performance standards for antimicrobial disk susceptibility tests*, 7th ed., National Committee for Clinical Laboratory Standards, Wayne, PA.

(51) Peet, N. P., Sunder, S., Barbuch, R. J., and Vinogradoff, A. P. (1986) Mechanistic observations in the Gewald syntheses of 2-aminothiophene. *J. Heterocycl. Chem.* 23, 129–134.

(52) Gewald, K., Schinke, E., and Böttcher, H. (1966) Heterocyclen aus CH-aciden nitrilen, VIII. 2-Amino-thiophene aus methylenaktiven nitrilen, carbonylverbindungen und schwefel. *Chem. Ber.* 99, 94–100.

(53) Khan, K. M., Nullah, Z., Lodhi, M. A., Jalil, S., Choudhary, M. I., and Rahman, A. U. (2006) Synthesis and anti-inflammatory activity of some selected aminothiophene analogs. *J. Enzym. Inhib. Med. Chem.* 21, 139–143.

(54) Manhas, M. S., Rao, V. V., and Amin, S. G. J. (1976) Heterocyclic compounds. VII. Synthesis of thiadiazasteroid analogs. *Heterocycl. Chem.* 13, 821–824.

(55) Hagen, H., Nilz, G., Walter, H., and Landes, A. (1995) Preparation of 2-aminothiophene derivatives as herbicide antidotes. U. S. Patent 5,442,335, June 6, 1995.

(56) Sugiyama, M., Sakamoto, T., Tabata, K., Endo, K., Ito, K., Kobayashi, M., and Fukumi, H. (1989) Condensed thienopyrimidines. I. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidin-5-one derivatives. *Chem. Pharm. Bull.* 37, 2091–2102.

(57) Yoshimura, Y., Kuze, T., Ueno, M., Komiya, F., Haraguchi, K., Tanaka, H., Kano, F., Yamada, K., Asami, K., Kaneko, N., and Takahata, H. (2006) A Practical synthesis of 4'-thioribonucleosides. *Tetrahedron Lett.* 47, 591–594.

(58) Hughes, N. A., Kuhajda, K.-M., and Miljkovic, D. A. (1994) New syntheses of methyl 5-thio- β -D-arabinopyranoside and (+) biotin. *Carbohydr. Res.* 257, 299–304.

(59) Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: A new

approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 11729–1749.

(60) Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J., Honig, B., Shaw, D. E., and Friesner, R. A. (2004) A hierarchical approach to allatom protein loop prediction. *Proteins* 55, 351–367.

(61) Kaminski, G. A., Friesner, R. A., Tirado-Rives, J., and Jorgensen, W. L. J. (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. *Phys. Chem. B* 105, 6474–6487.

(62) Yu, Z., Jacobson, M. P., and Friesner, R. A. (2006) What role do surfaces play in GB models? A new-generation of surface-generalized born model based on a novel Gaussian surface for biomolecules. *J. Comput. Chem.* 27, 72–89.

(63) García-Iópez, J., Hernández-Mateo, F., Isac-García, J., Kim, J., Roy, R., Santoyo-González, F., and Vergas-Berengeul, A. (1999) Synthesis of per-glycosylated β -cyclodextrines having enhanced lectin binding affinity. J. Org. Chem. 64, 522–531.

(64) Skaanderup, P. R., Poulsen, C. S., Hyldtoft, L., Jorgensen, M. R., and Madsen, R. (2002) Regioselective conversion of primary alcohols into iodides in unprotected methyl furanosides and pyranosides. *Synthesis* 12, 1721–1727.

NOTE ADDED AFTER ASAP PUBLICATION

This paper was published on the Web on Dec 10, 2012, with errors in Scheme 3. The corrected version was reposted on Dec 19, 2012.